D-phenylalanine and other enkephalinase inhibitors as pharmacological agents: implications for some important therapeutic application.
A number of compounds have been shown to inhibit the degradation of enkephalins. As expected, these compounds produce naloxone reversible analgesia and potentiate the analgesia produced by enkephalins and by acupuncture. One of these, D-phenylalanine, is also anti-inflammatory. D-phenylalanine has proven to be beneficial in many human patients with chronic, intractable pain. It is proposed the enkephalinase inhibitors may be effective in a number of human "endorphin deficiency diseases" such as depression, schizophrenia, convulsive disorders and arthritis. Such compounds may alleviate other conditions associated with decreased endorphin levels such as opiate withdrawal symptoms.
D015670:Acupuncture Therapy; D000698:Analgesia; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001711:Biotransformation; D004723:Endorphins / Q000378:metabolism*; D004745:Enkephalins / Q000378:metabolism; D005544:Forecasting; D006801:Humans; D015260:Neprilysin; D010148:Intractable Pain / Q000188:drug therapy*; D010649:Phenylalanine / Q000494:pharmacology*; D011480:Protease Inhibitors
D000893:Anti-Inflammatory Agents; D004723:Endorphins; D004745:Enkephalins; D011480:Protease Inhibitors; D010649:Phenylalanine; D015260:Neprilysin